IR-Med appoints healthcare exec Tzur Di-Cori as CEO; PressureSafe commercial launch pending approval

IR-Med, Inc.

Tzur Di-Cori appointed CEO effective Oct 15, 2023; previously President/CEO of LifeWatch Technologies and other healthcare firms.
Receives monthly salary of NIS 45,000 (~$11,842) and options for 1,000,000 shares at $0.58, vesting over 4 years.
Chairman Oded Bashan remains Chairman; commercial launch of PressureSafe expected in current quarter pending regulatory approval.
Di-Cori's previous roles include CEO of Motorika Medical, Veoli, DUSMIT; no family relationships with directors.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tzur Di-Cori

Chief Executive Officer

IR-Med, Inc.

Effective: 2023-10-15
Filed: October 4, 2023, 7:59 PM ET

Effective as of October 15, 2023, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Mr. Tzur Di-Cori to serve as its Chief Executive Officer (CEO), effective October 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Tzur Di-Cori was appointed as Chief Executive Officer at IR-Med, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective as of October 15, 2023, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Mr. Tzur Di-Cori to serve as its Chief Executive Officer (CEO), effective October 15, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-23-035696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.